800-401-4720
Recent Posts
Categories
Archives
Dangerous Drugs
Injuries
Contact Us
Dangerous Drugs and Injuiries Attorneys
Dangerous Drugs and Injuries Lawyers Who We Are What We Do Frequently Asked Questions Contact Us
We Sue Companies That Sell Dangerous Drugs
Nationwide Law Practice click here to be instantly connected to our office Medical and Legal News
« Federal Judge Rejects GE Healthcare Arguments to Exclude Expert Testimony on Cause of NSF | Main  | The Cleveland Plain Dealer Reports Fleet Settlement Coming Soon »
  FDA Announces “Bad Ad Program” to Help Health Care Providers Detect and Report Misleading Drug Ads
Today, the U.S. Food and Drug Administration announced the launch of what it calls the “Bad Ad Program.”  The program is designed to educate health care providers about their role in ensuring that prescription drug advertising and promotion is truthful and not misleading.

The program is aimed at drug ads that target doctors and other health care providers.  The pharmaceutical industry spends three times as much on advertising directed at health care professionals as it spends on advertising directed at consumers.  Advertising directly to health care professionals is called “detailing,” and most frequently occurs in locations such as medical offices, hospitals, and pharmacies, as well as at medical meetings and symposia.

A document released today by the FDA describes the main purpose of the Bad Ad Program as raising “awareness among health care professionals about the importance of helping FDA in its efforts to prevent misleading promotion of prescription drugs.”  According to Thomas Abrams, director of the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC), “the Bad Ad Program will help health care providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency.”

When reports of misleading ads are filed, the DDMAC will determine whether it meets the criteria necessary for taking regulatory action.  If the DDMAC determines the ad to be a violation, it will move forward with an appropriate enforcement action, which could include sending a Warning Letter or referring the matter to law enforcement for a criminal investigation.

Although the Bad Ad Program is mainly aimed at health care professionals, anyone can submit a complaint to the FDA.  The FDA has a similar educational campaign designed to educate consumers about misleading drugs advertisements.  This program is called EthicAd and may be accessed on the internet HERE.

If you believe you have been injured by a prescription drug or over-the-counter drug, you also can report this to the FDA HERE.  This is not necessary to preserve your legal rights, but it is the right thing to do, because it can bring dangerous drug side effects to the attention of the FDA, and make sure the FDA is aware how dangerous a particular drug is.

FDA Documents on the Bad Ad Program:

Posted By DeCarli Law on May 11, 2010 09:29 pm | Permalink 

Comments

No Comments Posted
Attorney Web Design The information on this website is for general information purposes only. Nothing on this or associated pages, documents, comments, answers, emails, or other communications should be taken as legal advice for any individual case or situation. The information on this website is not intended to create, and receipt or viewing of this information does not constitute, an attorney-client relationship. DeCarli Law only represents individuals pursuant to a signed, written contract.

Address: 50 California Street, Suite 1500 San Francisco CA 94111 Toll Free: 1-800-401-4720 Phone: 1-415-738-6144
Debra DeCarli and Bob DeCarli are licensed by the State Bar of Texas and the State Bar of California.

DeCarli Law represents drug side effects and defective medical devices personal injury clients for claims, lawsuits and settlements in Alabama AL, Alaska AK, Arizona AZ, Arkansas AR, California CA, Colorado CO, Connecticut CT, Delaware DE, Georgia GA, Hawaii HI, Idaho ID, Illinois IL, Kansas KS, Maine ME, Maryland MD, Massachusetts MS, Minnesota MN, Mississippi MS, Montana MT, Nebraska NE, New Hampshire NH, New Jersey NJ, New Mexico NM, New York NY, North Carolina NC, North Dakota ND, Oklahoma OK, Oregon OR, Rhode Island RI, South Carolina SC, South Dakota SD, Tennessee TN, Utah UT, Vermont VT, Virginia VA, Washington WA, Washington D.C, West Virginia WV, Wisconsin WI and Wyoming WY. The attorneys of DeCarli Law are licensed in California and Texas. DeCarli Law's practice includes lawsuits for Propecia side effects, Finasteride lawsuits, Topamax lawsuits, Fosamax lawsuits, Gadolinium lawsuits, NSF lawsuits, Nephrogenic Systemic Fibrosis Lawsuits, YAZ lawsuits, Yasmin lawsuits, Ocella lawsuits, and Zarah lawsuits.